Tscan Historical Cash Flow

TCRX Stock  USD 4.52  0.26  6.10%   
Analysis of Tscan Therapeutics cash flow over time is an excellent tool to project Tscan Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 85.9 M or Other Cashflows From Financing Activities of 50.2 M as it is a great indicator of Tscan Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Tscan Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tscan Therapeutics is a good buy for the upcoming year.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

About Tscan Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Tscan balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Tscan's non-liquid assets can be easily converted into cash.

Tscan Therapeutics Cash Flow Chart

At this time, Tscan Therapeutics' Change In Cash is fairly stable compared to the past year. Change In Working Capital is likely to rise to about 18.5 M in 2024, despite the fact that Investments are likely to grow to (60.8 M).

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Tscan Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Tscan Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from Tscan Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Tscan Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.At this time, Tscan Therapeutics' Change In Cash is fairly stable compared to the past year. Change In Working Capital is likely to rise to about 18.5 M in 2024, despite the fact that Investments are likely to grow to (60.8 M).
 2022 2023 2024 (projected)
Stock Based Compensation4.6M5.2M2.9M
Net Borrowings29.0M26.1M23.4M

Tscan Therapeutics cash flow statement Correlations

0.00.94-0.720.71-0.67-0.58-0.70.06-0.350.71-0.10.87-0.62-0.840.020.790.780.58
0.00.08-0.1-0.08-0.19-0.42-0.060.860.550.450.80.050.35-0.09-0.130.370.380.45
0.940.08-0.590.66-0.64-0.51-0.580.16-0.290.71-0.020.8-0.5-0.80.060.780.770.62
-0.72-0.1-0.59-0.940.190.930.990.180.56-0.820.11-0.950.890.95-0.01-0.9-0.91-0.84
0.71-0.080.66-0.94-0.1-0.85-0.95-0.33-0.690.79-0.230.94-0.94-0.960.110.870.870.84
-0.67-0.19-0.640.19-0.10.150.19-0.320.08-0.180.14-0.410.030.330.55-0.33-0.32-0.11
-0.58-0.42-0.510.93-0.850.150.92-0.070.38-0.88-0.15-0.860.70.880.05-0.93-0.94-0.94
-0.7-0.06-0.580.99-0.950.190.920.240.64-0.790.18-0.950.910.950.06-0.89-0.89-0.84
0.060.860.160.18-0.33-0.32-0.070.240.810.30.87-0.140.60.110.060.170.170.14
-0.350.55-0.290.56-0.690.080.380.640.81-0.120.83-0.60.830.570.34-0.32-0.32-0.33
0.710.450.71-0.820.79-0.18-0.88-0.790.3-0.120.40.82-0.57-0.870.290.960.970.93
-0.10.8-0.020.11-0.230.14-0.150.180.870.830.4-0.180.480.10.440.180.190.23
0.870.050.8-0.950.94-0.41-0.86-0.95-0.14-0.60.82-0.18-0.86-0.99-0.060.930.930.83
-0.620.35-0.50.89-0.940.030.70.910.60.83-0.570.48-0.860.85-0.05-0.68-0.68-0.63
-0.84-0.09-0.80.95-0.960.330.880.950.110.57-0.870.1-0.990.85-0.03-0.95-0.95-0.88
0.02-0.130.06-0.010.110.550.050.060.060.340.290.44-0.06-0.05-0.030.080.080.07
0.790.370.78-0.90.87-0.33-0.93-0.890.17-0.320.960.180.93-0.68-0.950.081.00.95
0.780.380.77-0.910.87-0.32-0.94-0.890.17-0.320.970.190.93-0.68-0.950.081.00.95
0.580.450.62-0.840.84-0.11-0.94-0.840.14-0.330.930.230.83-0.63-0.880.070.950.95
Click cells to compare fundamentals

Tscan Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.